{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Diouf I"],"funding":["Roche","National Health and Medical Research Council"],"pagination":["1014-1024"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10946605"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["30(4)"],"pubmed_abstract":["<h4>Background and purpose</h4>This study assessed the effect of patient characteristics on the response to disease-modifying therapy (DMT) in multiple sclerosis (MS).<h4>Methods</h4>We extracted data from 61,810 patients from 135 centers across 35 countries from the MSBase registry. The selection criteria were: clinically isolated syndrome or definite MS, follow-up ≥ 1 year, and Expanded Disability Status Scale (EDSS) score ≥ 3, with ≥1 score recorded per year. Marginal structural models with interaction terms were used to compare the hazards of 12-month confirmed worsening and improvement of disability, and the incidence of relapses between treated and untreated patients stratified by their characteristics.<h4>Results</h4>Among 24,344 patients with relapsing MS, those on DMTs experienced"],"journal":["European journal of neurology"],"pubmed_title":["Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis."],"pmcid":["PMC10946605"],"funding_grant_id":["1080518","1129189","1140766"],"pubmed_authors":["Alroughani R","Slee M","Kalincik T","Deri N","Hamdy S","Khurana D","Karabudak R","Sola P","Vucic S","Yamout B","Shaygannejad V","Hughes S","Maimone D","van der Walt A","Lugaresi A","Van Wijmeersch B","Al-Asmi A","McCombe P","Van Hijfte L","Havrdova EK","Ozakbas S","Sinnige LGF","Iuliano G","de Gans K","Buzzard K","Ferraro D","Sa MJ","McGuigan C","Kappos L","Macdonell R","Duquette P","Solaro C","Grammond P","Trevino-Frenk I","Prat A","Diouf I","Turkoglu R","Boz C","van Pesch V","Shaw C","Horakova D","Csepany T","Cristiano E","Perez Sempere A","Schepel J","Blanco Y","Bergamaschi R","Patti F","Cartechini E","Gouider R","Gerlach O","Lechner-Scott J","Roos I","Aguera-Morales E","Laureys G","Altintas A","Ramo-Tello C","Onofrj M","Barnett M","Spitaleri D","Izquierdo G","Eichau S","Girard M","Al-Harbi T","Malpas CB","Grand'Maison F","Butler E","Skibina O","Prevost J","Castillo-Trivino T","Gray O","Granella F","Butzkueven H","Soysal A","Terzi M","Petersen T","Sanchez-Menoyo JL","Fragoso Y","Hodgkinson S","Ampapa R","Moore F","Sharmin S"],"additional_accession":[]},"is_claimable":false,"name":"Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis.","description":"<h4>Background and purpose</h4>This study assessed the effect of patient characteristics on the response to disease-modifying therapy (DMT) in multiple sclerosis (MS).<h4>Methods</h4>We extracted data from 61,810 patients from 135 centers across 35 countries from the MSBase registry. The selection criteria were: clinically isolated syndrome or definite MS, follow-up ≥ 1 year, and Expanded Disability Status Scale (EDSS) score ≥ 3, with ≥1 score recorded per year. Marginal structural models with interaction terms were used to compare the hazards of 12-month confirmed worsening and improvement of disability, and the incidence of relapses between treated and untreated patients stratified by their characteristics.<h4>Results</h4>Among 24,344 patients with relapsing MS, those on DMTs experienced","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Apr","modification":"2025-04-20T02:49:06.144Z","creation":"2025-02-19T03:09:22.165Z"},"accession":"S-EPMC10946605","cross_references":{"pubmed":["36692895"],"doi":["10.1111/ene.15706"]}}